Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An announcement from Immunovia AB ( (SE:IMMNOV) ) is now available.
Immunovia announced that its PancreaSure test will be incorporated into the Inova Schar Cancer high-risk surveillance program to improve early detection and outcomes for pancreatic cancer patients. The test, which has shown high accuracy in clinical studies, is expected to enhance the capabilities of the surveillance program and strengthen Immunovia’s position in the pancreatic cancer diagnostics industry.
More about Immunovia AB
Immunovia AB is a diagnostic company focused on increasing survival rates for pancreatic cancer patients through early detection. The company specializes in developing and commercializing blood-based tests to detect proteins and antibodies indicative of pancreatic cancer, collaborating with healthcare providers, experts, and advocacy groups to serve high-risk individuals.
YTD Price Performance: 16.30%
Average Trading Volume: 10,274,017
Technical Sentiment Signal: Hold
Current Market Cap: SEK194.4M
For an in-depth examination of IMMNOV stock, go to TipRanks’ Overview page.